SPRY: ARS Pharma P/S Multiple

Brandmark of ARS Pharma (SPRY)

ARS Pharmaceuticals generates revenue through the sale of innovative emergency care products, offering a needle-free nasal spray for allergy relief. The GURU.Markets terminal displays a chart of the company's market cap-to-revenue ratio, where the 3.10 metric serves as the target level. Revenues are based on sales of the drug neffy, creating a unique therapy ecosystem that attracts patients who fear injections, despite FDA regulatory risks.

SPRY: ARS Pharmaceuticals, Inc. Price-to-Revenue Ratio 04/28/2023 - 11/13/2026

Metric breakdowns and analytics for ARS Pharma (SPRY)

- share price and consensus valuation forecast:
Price Performance Chart ars-pharma.com|SPRY - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization ARS Pharma|SPRY - Total Company Value
- balance sheet equity data:
Accounting Value of a Share ARS Pharmaceuticals|SPRY - Company Book Value|Market Capitalization to Book Value ars-pharma.com|SPRY - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio ARS Pharmaceuticals|SPRY - Long-Term Debt to Equity|Current Liabilities to Equity ARS Corp|SPRY - Company Aggregate Debts|Debt to Net Assets Ratio ARS Pharma|SPRY - Company Long-Term Debts|Company Short-Term Debts ARS Pharmaceuticals|Intermediate Coverage Ratio ars-pharma.com
- earnings and valuation multiples information:
SPRY - Company Net Income|Future Profit ARS Pharmaceuticals|SPRY - P/E Multiple|Forward P/E Multiple ARS Pharmaceuticals Inc|SPRY - PEG Multiple|Enterprise Value to EBITDA Ratio ARS Pharma|SPRY - Operating profit EBITDA|Net earnings per one share for the last twelve months ARS Pharmaceuticals|SPRY - Net earnings per share for the last 12 months|Quarterly EPS earnings growth ars-pharma.com|SPRY - Net earnings per share growth this year|Projected earnings per share increase next year ARS Pharmaceuticals
- total revenue and sales volume data:
SPRY - Revenue and Sales Volume|Company Future Sales ars-pharma.com|SPRY - P/S Multiple|Forward Price-to-Revenue Multiple ARS Pharma
General company analysis:ars-pharma.com, SPRY
Finished products of ARS Pharmaceuticals Inc

Future revenues for ARS Pharmaceuticals (SPRY) depend on the commercial success of the neffy nasal spray, making a market valuation analysis based on revenue critically important. The price/sales ratio reflects the relationship between market capitalization and actual sales, allowing investors to assess the extent to which market expectations are inflated relative to the current scale of the business and to determine the risk of a potential asset correction.

Competing companies

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple KVUE (Kenvue)|P/S Multiple Verona Pharma PLC VRNA|MENS - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio LGND (Ligand Corp)|Amneal Pharmaceuticals (AMRX) - Price-to-Revenue Ratio|PRGO - Price-to-Revenue Coefficient|Market Cap to Revenue ALVO|LQDA: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Price-to-Sales Ratio|P/S Multiple MNKD (MannKind Corporation)|Market Capitalization-to-Revenue Ratio AMPH|Pacira BioSciences, Inc. - P/S Multiple|TBPH - P/S Multiple|Aquestive Pharma (AQST) - Price-to-Revenue Ratio|scPharmaceuticals - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Tectonic Therapeutic Inc.|Market Cap to Revenue tonixpharma.com (TNXP)|P/S Multiple SXTC|P/S Multiple eupraxiapharma.com (EPRX)|P/S Multiple BHST (BioHarvest)|EXOZ - Market Cap to Revenue|Oramed Pharma - P/S Multiple|Price to Sales Entera Bio Ltd.|HYFT (MindWalk Holdings Inc.) - Market Cap to Revenue|ABVC BioPharma Inc. (ABVC) - P/S Multiple|Market Cap to Revenue CPIX|QNTM (Quantum BioPharma Corp) - Market Cap to Sales Volume|P/S Multiple FGEN|Price-to-Revenue Coefficient telomirpharma.com|P/S Multiple RANI (Rani Therapeutics Holdings, Inc.)|SNYR - Market Cap to Revenue|Rallybio Corp. - P/S Multiple|LEXX - P/S Multiple|Pulmatrix, Inc. (PULM) - Price-to-Revenue Ratio|PTHL (Pheton Holdings) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Aptorum Group Ltd|Lyra Therapeutics Inc. (LYRA) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Impact BioMedical (IBO)|Price-to-Revenue Coefficient tnfpharma.com|Price-to-Revenue Ratio cbdMD YCBD|PRFX (painreform.com) - Price-to-Sales Ratio|CYTO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio LIPO (Lipella Pharmaceuticals Inc)|OPTN (Optinose) - Market Cap to Revenue|Price to Sales Pieris Pharma (PIRS)|Price-to-Revenue Ratio Procaps Group S.A.|petrospharma.com - Price-to-Sales Ratio|P/S Multiple QLI|SLRN (Acelyrin Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple TFFP (TFF Pharma)